Compare SPOK & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPOK | CVRX |
|---|---|---|
| Founded | 2004 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.7M | 237.1M |
| IPO Year | 2004 | 2021 |
| Metric | SPOK | CVRX |
|---|---|---|
| Price | $11.11 | $7.03 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $14.00 | $10.50 |
| AVG Volume (30 Days) | 132.3K | ★ 248.6K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 10.90% | N/A |
| EPS Growth | 2.74 | ★ 23.02 |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $139,708,000.00 | $56,651,000.00 |
| Revenue This Year | $1.70 | $17.17 |
| Revenue Next Year | N/A | $17.69 |
| P/E Ratio | $15.27 | ★ N/A |
| Revenue Growth | 1.49 | ★ 10.45 |
| 52 Week Low | $10.81 | $4.37 |
| 52 Week High | $19.31 | $11.30 |
| Indicator | SPOK | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.12 | 38.92 |
| Support Level | $10.87 | $6.74 |
| Resistance Level | $11.56 | $8.93 |
| Average True Range (ATR) | 0.23 | 0.57 |
| MACD | 0.05 | -0.06 |
| Stochastic Oscillator | 26.85 | 20.44 |
Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.